Oliver Klein

Dr. Oliver Klein

orcid

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 November 2018 in Proteomics – Clinical Applications
Verified
Journal Article
Closed access
PDF file
OKOliver Klein
Oliver Klein
FKFrederic Kanter
Frederic Kanter
HKHagen Kulbe
Hagen Kulbe
PJPaul Jank
Paul Jank
CDCarsten Denkert
Carsten Denkert
ETEliane Tabea Taube
Eliane Tabea Taube

23 July 2014 in Proteomics
Verified
Journal Article
Closed access
PDF file
OKOliver Klein
Oliver Klein
KSKristin Strohschein
Kristin Strohschein
GNGrit Nebrich
Grit Nebrich
JOJanina Oetjen
Janina Oetjen
DTDennis Trede
Dennis Trede
TWTobias Winkler
Tobias Winkler

Verified
Journal Article
Open access
PDF file
MBMatthias Becker
Matthias Becker
JMJanita A. Maring
Janita A. Maring
MSMaria Schneider
Maria Schneider
AMAaron Xerach Herrera Martin
Aaron Xerach Herrera Martin
MSMartina Seifert
Martina Seifert
Christof StammChristof Stamm
Christof Stamm
There is a growing need for scaffold material with tissue-specific bioactivity for use in regenerative medicine, tissue engineering, and for surgical repair of structural defects. We developed a novel composite biomaterial by processing human cardiac extracellular matrix (ECM) into a hydrogel and combining it with cell-free amniotic membrane via a dry-coating procedure. Cardiac biocompatibility and immunogenicity were tested in vitro using human cardiac fibroblasts, epicardial progenitor cells, murine HL-1 cells, and human immune cells derived from buffy coat. Processing of the ECM preserved important matrix proteins as demonstrated by mass spectrometry. ECM coating did not alter the mechanical characteristics of decellularized amniotic membrane but did cause a clear increase in adhesion capacity, cell proliferation and viability. Activated monocytes secreted less pro-inflammatory cytokines, and both macrophage polarization towards the pro-inflammatory M1 type and T cell proliferation were prevented. We conclude that the incorporation of human cardiac ECM hydrogel shifts and enhances the bioactivity of decellularized amniotic membrane, facilitating its use in future cardiac applications.

22 March 2023 in Science Translational Medicine
Verified
Journal Article
Closed access
SHSarah Hochmann
Sarah Hochmann
KOKristy Ou
Kristy Ou
RPRodolphe William Poupardin
Rodolphe William Poupardin
MMMichaela Mittermeir
Michaela Mittermeir
MTMartin Textor
Martin Textor
DSDirk Strunk
Dirk Strunk
Multipotent stromal cells are considered attractive sources for cell therapy and tissue engineering. Despite numerous experimental and clinical studies, broad application of stromal cell therapeutics is not yet emerging. A major challenge is the functional diversity of available cell sources. Here, we investigated the regenerative potential of clinically relevant human stromal cells from bone marrow (BMSCs), white adipose tissue, and umbilical cord compared with mature chondrocytes and skin fibroblasts in vitro and in vivo. Although all stromal cell types could express transcription factors related to endochondral ossification, only BMSCs formed cartilage discs in vitro that fully regenerated critical-size femoral defects after transplantation into mice. We identified cell type–specific epigenetic landscapes as the underlying molecular mechanism controlling transcriptional stromal differentiation networks. Binding sites of commonly expressed transcription factors in the enhancer and promoter regions of ossification-related genes, including Runt and bZIP families, were accessible only in BMSCs but not in extraskeletal stromal cells. This suggests an epigenetically predetermined differentiation potential depending on cell origin that allows common transcription factors to trigger distinct organ-specific transcriptional programs, facilitating forward selection of regeneration-competent cell sources. Last, we demonstrate that viable human BMSCs initiated defect healing through the secretion of osteopontin and contributed to transient mineralized bone hard callus formation after transplantation into immunodeficient mice, which was eventually replaced by murine recipient bone during final tissue remodeling.

1 October 2020 in Biomaterials
Verified
Journal Article
Closed access
ADAssal Daneshgar
Assal Daneshgar
OKOliver Klein
Oliver Klein
GNGrit Nebrich
Grit Nebrich
MWMarie Weinhart
Marie Weinhart
PTPeter Tang
Peter Tang
KHKarl Herbert Hillebrandt
Karl Herbert Hillebrandt

25 March 2021 in Cancers
Verified
Journal Article
Open access
PDF file
WKWanja Kassuhn
Wanja Kassuhn
OKOliver Klein
Oliver Klein
SDSilvia Darb-Esfahani
Silvia Darb-Esfahani
HLHedwig Lammert
Hedwig Lammert
SHSylwia Handzik
Sylwia Handzik
IBIoana Braicu
Ioana Braicu
Despite the correlation of clinical outcome and molecular subtypes of high-grade serous ovarian cancer (HGSOC), contemporary gene expression signatures have not been implemented in clinical practice to stratify patients for targeted therapy. Hence, we aimed to examine the potential of unsupervised matrix-assisted laser desorption/ionization imaging mass spectrometry (MALDI-IMS) to stratify patients who might benefit from targeted therapeutic strategies. Molecular subtyping of paraffin-embedded tissue samples from 279 HGSOC patients was performed by NanoString analysis (ground truth labeling). Next, we applied MALDI-IMS paired with machine-learning algorithms to identify distinct mass profiles on the same paraffin-embedded tissue sections and distinguish HGSOC subtypes by proteomic signature. Finally, we devised a novel approach to annotate spectra of stromal origin. We elucidated a MALDI-derived proteomic signature (135 peptides) able to classify HGSOC subtypes. Random forest classifiers achieved an area under the curve (AUC) of 0.983. Furthermore, we demonstrated that the exclusion of stroma-associated spectra provides tangible improvements to classification quality (AUC = 0.988). Moreover, novel MALDI-based stroma annotation achieved near-perfect classifications (AUC = 0.999). Here, we present a concept integrating MALDI-IMS with machine-learning algorithms to classify patients according to distinct molecular subtypes of HGSOC. This has great potential to assign patients for personalized treatment.